Dementia affects 55 million people globally, with the number projected to triple by 2050. Statins, widely prescribed for cardiovascular benefits, may also have neuroprotective effects, although studies on their impact on dementia risk have shown contradictory results.
Is it safe to take statins in terms of brain health? So many patients at the Kahn Center express there fear of having brain damage from statins so new information is crucial.
In this systematic review and meta-analysis, we searched PubMed, Embase, and Cochrane databases for studies on statin medications and brain health.
The authors assessed the risk of dementia, Alzheimer's disease (AD), and vascular dementia (VaD), with subgroup analyses by gender, statin type, and diabetes status. Fifty-five observational studies including over 7 million patients were analyzed.
Statin use significantly reduced the risk of dementia compared to nonusers by 14%.
It was also associated with reduced risks of AD by 18% and VaD by 11%.
Subgroup analyses revealed significant dementia risk reductions among patients with type 2 diabetes mellitus by 13%, those with exposure to statins for more than 3 years by 63%, and populations from Asia, where the greatest protective effect was observed by 16%.
Additionally, rosuvastatin demonstrated the most pronounced protective effect for all-cause dementia among specific statins by 28%.
The research findings underscore the neuroprotective potential of statins in dementia prevention.
Despite the inherent limitations of observational studies, the large dataset and detailed subgroup analyses enhance the reliability of our results.
Future randomized clinical trials are necessary to confirm these findings and enlighten clinical guidelines.
From the perspective of the Kahn Center, if it is advised to take a statin Rx, as low a dose as possible, combined with CoQ10, fearing brain health is misdirected.
